KAHR Medical

Company Overview

Snapshot

Founded in September 2005, KAHR Medical operates with 11–50 employees. The company has raised $140.27 million across 13 funding rounds from 18 investors. In January 2026, KAHR Medical announced strong topline Phase 2 results for its lead candidate DSP107 in combination with anti-PD-L1 therapy for colorectal cancer, with.

Business overview

KAHR Medical is a clinical-stage biotechnology company focused on developing immuno-oncology drug candidates for various cancer types. The company's core technology is based on multifunctional immuno-recruitment proteins (MIRP), which selectively target tumors by utilizing the overexpression of checkpoint antigens on cancer cells. These MIRPs bridge cancer cells to immune cells, combining immune checkpoint inhibition with localized immune cell activation to unmask cancer cells and recruit the adaptive immune system for targeted cell killing. KAHR Medical's lead product, DSP107, is a CD47x41BB targeting compound designed to simultaneously target cancer cells, weaken their defenses, and activate both innate and adaptive immunity. The company operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, targeting the biopharmaceutical market.

Strategic signal

In January 2026, KAHR Medical announced positive topline Phase 2 results for DSP107 in combination with anti-PD-L1 therapy for colorectal cancer. This milestone is significant as it validates the potential of KAHR's bispecific 4-1BB T-cell engager in a challenging indication, demonstrating clinical efficacy and advancing the company's lead candidate towards further development. For investors, this signals strong progress in KAHR's pipeline and potential for future market penetration in immuno-oncology.

Company Intelligence Q&A

What were the key findings from KAHR Medical's Phase 2 study of DSP107 in colorectal cancer?

In January 2026, KAHR Medical announced strong topline Phase 2 results for DSP107 in combination with anti-PD-L1 therapy for colorectal cancer. This data indicates positive clinical efficacy for their lead bispecific 4-1BB T-cell engager.

Which investors participated in KAHR Medical's January 2026 funding round?

In January 2026, KAHR Medical secured funding led by.

What strategic partnership did KAHR Medical establish in June 2021?

In June 2021, KAHR Medical announced a development and manufacturing agreement with Samsung Biologics for its cancer immunotherapy drug candidate. This collaboration aims to advance the production of KAHR's therapeutic pipeline.

When did KAHR Medical receive FDA clearance for clinical trials of its immunotherapy drug?

In August 2020, KAHR Medical received FDA clearance to begin clinical trials for its immunotherapy drug designed to treat cancer, marking a significant step towards human trials.

What was the focus of the investment KAHR Medical received from the Myeloma Investment Fund?

In November 2022, the Myeloma Investment Fund invested in.